NCT03803761 2023-09-25
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn
NCT00977795 2019-09-10
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Endeavor Health
Phase 1/2 Withdrawn
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00397501 2017-04-21
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
OHSU Knight Cancer Institute
Phase 1/2 Withdrawn
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT02521090 2016-02-15
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT00021307 2013-07-11
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Fox Chase Cancer Center
Phase 1/2 Withdrawn